Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer

Por Pal, Sumanta Kumar, Sartor, Oliver
Publicado em 2010

Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer

Por Pal, Sumanta Kumar, Sartor, Oliver
Publicado em 2011

The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy

Por Kortylewski, Marcin, Pal, Sumanta K
Publicado em 2014

Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer

Por Pal, Sumanta K., Kortylewski, Marcin
Publicado no Oncoimmunology (2015)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

Por Pal, Sumanta Kumar, Figlin, Robert A.
Publicado em 2010

Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling

Por Pal, Sumanta K., Reckamp, Karen L.
Publicado em 2010

Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in NSCLC

Por Pal, Sumanta K., Reckamp, Karen L.
Publicado em 2010

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Por Pal, Sumanta Kumar, Figlin, Robert A.
Publicado em 2011

Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer

Por Pal, Sumanta K., Stein, C. A.
Publicado em 2012

A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Posi...

Por Pal, Sumanta Kumar, Vogelzang, Nicholas J.
Publicado em 2012

Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future

Por Pal, Sumanta K., Haas, Naomi B.
Publicado em 2014

Differentiating mTOR Inhibitors in Renal Cell Carcinoma

Por Pal, Sumanta K., Quinn, David I.
Publicado no Cancer Treat Rev (2013)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Por Pal, Sumanta Kumar, Twardowski, Przemyslaw, Sartor, Oliver
Publicado em 2010

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Por Pal, Sumanta K., Lewis, Brian, Sartor, Oliver
Publicado em 2012

Radium-223 in metastatic castration resistant prostate cancer

Por Vuong, Winston, Sartor, Oliver, Pal, Sumanta K
Publicado em 2014

Management of localized prostate cancer: the pendulum swings (back to the middle)

Por Vuong, Winston, Sartor, Oliver, Pal, Sumanta K
Publicado em 2014

Lessons learned from Avastin

Por Mortimer, Joanne, Zonder, Helene, Pal, Sumanta K.
Publicado no Cancer Control (2012)

Deciphering the anticancer mechanisms of sunitinib

Por Pal, Sumanta Kumar, Figlin, Robert A, Yu, Hua
Publicado em 2010

Triple negative breast cancer: unmet medical needs

Por Pal, Sumanta Kumar, Childs, Barrett H., Pegram, Mark
Publicado em 2010

Targeted Therapies for Non-Small Lung Cancer: An Evolving Landscape

Por Pal, Sumanta Kumar, Figlin, Robert A., Reckamp, Karen
Publicado em 2010